Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05448950 · ClinicalTrials.gov registry record · NA
Continued Access Study VIG Anastomotic Connector
A NA study, sponsored by Phraxis.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT05448950 is a NA study that has completed, run by Phraxis. The registered enrollment target is 12 participants.
The verdict
NCT05448950, a NA study, has completed, sponsored by Phraxis.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The continued access study of the InterGraft Venous Anastomotic Connector (Venous InterGraft Continued Access Study, or 'VIG-CAS') allows for continued enrollment of subjects while the marketing application is being prepared and subsequently reviewed by FDA. The VIG-CAS will include the same patient population, follow-up schedule, and study endpoints as the VIG pivotal study.
Interventions
- DEVICE VIG Continued Access Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2023-03-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05448950
The ClinicalTrials.gov registry entry for NCT05448950 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phraxis, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VIG Continued Access Study is the first listed.
NCT05448950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05448950 about?
NCT05448950 is a clinical study titled "Continued Access Study VIG Anastomotic Connector". The continued access study of the InterGraft Venous Anastomotic Connector (Venous InterGraft Continued Access Study, or 'VIG-CAS') allows for continued enrollment of subjects while the marketing application is being prepared and subsequently reviewed by FDA. The VIG-CAS will include the same patient...
What is the current status of trial NCT05448950?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-06-07. Estimated completion is 2023-03-08.
What interventions are being tested in trial NCT05448950?
The interventions under investigation include: VIG Continued Access Study (DEVICE).
Who is sponsoring clinical trial NCT05448950?
This trial is sponsored by Phraxis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.